The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice
Open accessAbstract
Until recently, human coronaviruses (HCoVs), such as HCoV strain OC43 (HCoV-OC43), were mainly known to cause 15 to 30% of mild upper respiratory tract infections. In recent years, the identification of new HCoVs, including severe acute respiratory syndrome coronavirus, revealed that HCoVs can be highly pathogenic and can cause more severe upper and lower respiratory tract infections, including bronchiolitis and pneumonia. To date, no specific antiviral drugs to prevent or treat HCoV infections are available. We demonstrate that chloroquine, a widely used drug with well-known antimalarial effects, inhibits HCoV-OC43 replication in HRT-18 cells, with a 50% effective concentration (± standard deviation) of 0.306 ± 0.0091 μM and a 50% cytotoxic concentration (± standard deviation) of 419 ± 192.5 μM, resulting in a selectivity index of 1,369. Further, we investigated whether chloroquine could prevent HCoV-OC43-induced death in newborn mice. Our results show that a lethal HCoV-OC43 infection in newborn C57BL/6 mice can be treated with chloroquine acquired transplacentally or via maternal milk. The highest survival rate (98.6%) of the pups was found when mother mice were treated daily with a concentration of 15 mg of chloroquine per kg of body weight. Survival rates declined in a dose-dependent manner, with 88% survival when treated with 5 mg/kg chloroquine and 13% survival when treated with 1 mg/kg chloroquine. Our results show that chloroquine can be highly effective against HCoV-OC43 infection in newborn mice and may be considered as a future drug against HCoVs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Identification of a new human coronavirus
van der Hoek, L., Pyrc, K., Jebbink, M. F., Vermeulen-Oost, W., Berkhout, R. J. M., Wolthers, K. C., Wertheim-van Dillen, P. M. E., Kaandorp, J., Spaargaren, J., & Berkhout, B. (2004) · Nature Medicine · doi:10.1038/nm1024 · Cited by 1,886
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Woo, P. C. Y., Lau, S. K. P., Chu, C.-M., Chan, K.-H., Tsoi, H.-W., Huang, Y., Wong, B. H. L., Poon, R. W. S., Cai, J. J., Luk, W.-K., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.2.884-895.2005 · Cited by 1,525
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,268
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649
Self-citationA previously undescribed coronavirus associated with respiratory disease in humans
Fouchier, R. A. M., Hartwig, N. G., Bestebroer, T. M., Niemeyer, B., de Jong, J. C., Simon, J. H., & Osterhaus, A. D. M. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400762101 · Cited by 598
Vijgen, L., Keyaerts, E., Moës, E., Thoelen, I., Wollants, E., Lemey, P., Vandamme, A.-M., & Van Ranst, M. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1595-1604.2005 · Cited by 594
Self-citationNeuroinvasion by Human Respiratory Coronaviruses
Arbour, N., Day, R., Newcombe, J., & Talbot, P. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.8913-8921.2000 · Cited by 522
Coronavirus HKU1 and Other Coronavirus Infections in Hong Kong
Lau, S. K. P., Woo, P. C. Y., Yip, C. C. Y., Tse, H., Tsoi, H.-W., Cheng, V. C. C., Lee, P., Tang, B. S. F., Cheung, C. H. Y., Lee, R. A., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.02614-05 · Cited by 442
Cited by
Devaux, C. A., Rolain, J.-M., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,099
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105932 · Cited by 937
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
COVID-19: A promising cure for the global panic
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., et al. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138277 · Cited by 636
Hydroxychloroquine: From Malaria to Autoimmunity
Ben-Zvi, I., Kivity, S., Langevitz, P., & Shoenfeld, Y. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8243-x · Cited by 613
Host Factors in Coronavirus Replication
de Wilde, A. H., Snijder, E. J., Kikkert, M., & van Hemert, M. J. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_25 · Cited by 546
Touret, F., & de Lamballerie, X. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104762 · Cited by 541
Al-Bari, M. A. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv018 · Cited by 467
High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses.
Shen, L., Niu, J., Wang, C., Huang, B., Wang, W., Zhu, N., Deng, Y., Wang, H., Ye, F., Cen, S., et al. (2019) · Journal of Virology · doi:10.1128/jvi.00023-19 · Cited by 319
Andreani, J., Le Bideau, M., Duflot, I., Jardot, P., Rolland, C., Boxberger, M., Wurtz, N., Rolain, J.-M., Colson, P., La Scola, B., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104228 · Cited by 319
Insights from nanomedicine into chloroquine efficacy against COVID-19
Hu, T. Y., Frieman, M., & Wolfram, J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0674-9 · Cited by 317
Plantone, D., & Koudriavtseva, T. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0656-y · Cited by 305
Current pharmacological treatments for COVID‐19: What's next?
Scavone, C., Brusco, S., Bertini, M., Sportiello, L., Rafaniello, C., Zoccoli, A., Berrino, L., Racagni, G., Rossi, F., & Capuano, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15072 · Cited by 283
Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models
Delvecchio, R., Higa, L., Pezzuto, P., Valadão, A., Garcez, P., Monteiro, F., Loiola, E., Dias, A., Silva, F., Aliota, M., et al. (2016) · Viruses · doi:10.3390/v8120322 · Cited by 279
Tuccori, M., Convertino, I., Ferraro, S., Cappello, E., Valdiserra, G., Focosi, D., & Blandizzi, C. (2020) · Drug Safety · doi:10.1007/s40264-020-00965-w · Cited by 80
Yang, K.-C., Lin, J.-C., Tsai, H.-H., Hsu, C.-Y., Shih, V., & Hu, C.-M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00965-y · Cited by 39
Metadata
- Authors
- Keyaerts, E., Li, S., Vijgen, L., Rysman, E., Verbeeck, J., Van Ranst, M., & Maes, P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-08
- Volume
- 53
- Issue
- 8
- Pages
- 3416-3421
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2154775719
- Cited by
- 311
- References
- 27
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.